Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

Summary

Primary Objective: 1\. To assess the safety and toxicity of imatinib mesylate when given to patients with Ph (+) CML , ALL or AML within the first 100 days following allogeneic bone marrow or stem cell transplantation. Secondary Objectives: 1. To identify any clinically significant drug interactions with imatinib in the post-transplant setting. 2. To develop specific monitoring parameters for imatinib use when utilized in the early post-BMT setting. 3. To record one-year survival data in this patient cohort to assess any effect of early imatinib administration on this endpoint.

Timeline

Start

2003-08

Primary completion

2007-10

Completion

2007-10

Drugs

Indications